Effect of pneumococcal vaccine and research progress.docVIP

 PAGE \* MERGEFORMAT 31 Effect of pneumococcal vaccine and research progress Keywords: immune responses induced by Streptococcus pneumoniae Progress Streptococcus pneumoniae (Streptococcus pneumoniae, Sp) is a community-acquired respiratory tract infections is an important pathogenic micro-organisms, is another cause of bacterial infectious diseases, the world’s major pathogens, including not only common infections such as otitis media, sinusitis, etc., and even endanger the life, pneumonia, sepsis and meningitis and other diseases. Children are often the biggest victims. Children in developing countries, the nasopharynx of asymptomatic carriers generally, and very easy to spread to other susceptible populations or development of disease, so Sp vaccine Sp infection control in the increasingly prominent role. Sp In this paper, the composition of the vaccine, immunization effect and now some progress in vaccine development. A vaccine currently in use S.p Sp to pathogenic bacteria and their structure and related metabolites, including the capsule (capsule), hemolysin (pneumolysin), surface adhesin (pneumococcal surface adhesion), neuraminidase (neuraminidase). Capsule is not only a prerequisite for its virulence and capsular polysaccharide with base-type specificity, is grouping, type of foundation, so far Streptococcus pneumoniae can be divided into 46 groups, more than 90 type [1] . Capsule is S.p major factor. Sp after vaccination can make the body produce antibodies against the capsule, played the role of prevention of inflammatory diseases [2]. Streptococcus pneumoniae vaccine currently in use are mainly capsular polysaccharide vaccine, capsular  binding protein vaccine. 1.1 capsular polysaccharide vaccine PPV23 (1,2,3,4,5,6 B, 7F, 8,9 N, 9V, 10A, 11A, 12F, 14,15 B, 17F, 18C, 19A, 19F, 20,22 F, 23F, 33F) containing 23 kinds of Sp serotype capsular polysaccharide. Caused 90% of invasive Streptococcus pneumoniae in